Meanwhile, LEF1 has been identified as a useful diagnostic marker for the development, metastases, and poor prognoses in several cancers, including chronic lymphocytic leukemia (Menter et al, 2017), breast cancer (Gilles et al, 2003), liver cancer (Singhi et al, 2014), prostate cancer (Yang et al, 2006). Here, LEF1 is linked to prostate carcinoma.